Tesamorelin + AOD-9604 Visceral Fat Research Stack
GHRH analogue + GH lipolytic fragment research stack targeting visceral adipose tissue. Two-peptide protocol with documented preclinical evidence.
The Tesamorelin + AOD-9604 combination is one of the most mechanistically coherent two-peptide stacks in metabolic research. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a unique published evidence base — the only GHRH-axis peptide to have completed Phase III randomised controlled trials resulting in FDA approval for visceral adipose tissue (VAT) reduction in HIV-associated lipodystrophy. AOD-9604 is the C-terminal lipolytic fragment of native human growth hormone (hGH residues 176–191), engineered to isolate the fat-mobilising signal of GH without engaging the IGF-1 axis. Together they represent a dual-pathway approach to visceral fat: proximal GHRH-receptor activation driving GH pulse amplitude, combined with direct adipocyte lipolysis at the receptor level. Both compounds remain unapproved for general use in the UK; this page summarises in vitro, animal-model and published clinical-trial evidence on the rationale and protocol for the combination — not advice on human administration.
Why stack Tesamorelin and AOD-9604?
The two peptides converge on visceral adipolysis through separate, non-competing mechanisms that operate at different points in the GH–fat axis.
Tesamorelin binds and activates the pituitary GHRH receptor, amplifying endogenous GH pulse amplitude and restoring the pulsatile GH secretion pattern that declines with age and metabolic disease. This sustained GH signal drives downstream lipolysis through hormone-sensitive lipase (HSL) activation in adipocytes — a systemic, axis-level effect. Crucially, the clinical evidence from Falutz and Stanley's Phase III programmes demonstrates that the Tesamorelin-driven VAT reduction is anatomically selective: subcutaneous fat is largely spared while visceral depots contract, a finding replicated across multiple trial cohorts [PMID:18057339].
AOD-9604, by contrast, acts peripherally and directly. As the GH C-terminal domain, it engages the same beta-adrenergic and HSL pathways as intact GH within the adipocyte, but does so without occupying the full GH receptor in a manner that elevates IGF-1 or glucose. This gives it a complementary profile: direct lipolytic action on adipocytes that is additive to the axis-level signal from Tesamorelin, without compounding the insulin-resistance risk associated with supraphysiological GH.
Mechanism of action — each peptide
Tesamorelin — mechanism of action
Tesamorelin is a 44-amino-acid GHRH analogue in which a trans-3-hexenoic acid group is added to the N-terminus to protect against dipeptidyl peptidase IV (DPP-IV) cleavage. This modification extends the plasma half-life from the approximately 2–3 minutes of native GHRH to roughly 20–30 minutes under subcutaneous conditions — sufficient to drive a discrete GH pulse following each injection.
The documented mechanism in published research includes:
- GHRH receptor (GHRHR) agonism at somatotrophic pituitary cells, increasing cAMP and PKA activity and augmenting GH secretion in a pulsatile, physiological pattern rather than the continuous supraphysiological elevation associated with exogenous GH.
- VAT-selective lipolysis — in the Falutz Phase III programme, the reduction in trunk fat was attributable almost entirely to the visceral compartment, with the proposed mechanism being higher density of GH receptors and HSL expression in visceral versus subcutaneous depots.
- Hepatic fat modulation — Fourman et al. (2017) documented significant reductions in liver fat fraction and alanine aminotransferase (ALT) in HIV-positive subjects treated with Tesamorelin 2 mg/d for 26 weeks [PMID:28692534], suggesting an indirect hepatic effect downstream of VAT reduction and improved hepatic lipid flux.
- Minimal IGF-1 supra-elevation — unlike exogenous GH at fat-mobilising doses, Tesamorelin produces IGF-1 increases that remain within or near the upper physiological range, reducing the risk of glucose dysregulation at study doses.
AOD-9604 — mechanism of action
AOD-9604 corresponds to residues 176–191 of human growth hormone, the C-terminal alpha-helical domain that confers the lipolytic activity of the intact GH molecule. It was isolated by Ng and colleagues at Monash University in the late 1990s as part of a programme to separate GH's anabolic and lipolytic domains.
The compound's documented mechanisms in animal-model and in vitro research include:
- Direct beta-3 adrenergic receptor stimulation in adipocytes — documented in Heffernan et al. (2000) rodent studies in which AOD-9604 produced dose-dependent fat mass reduction in obese mice without affecting lean mass or fasting insulin [PMID:10950816].
- Hormone-sensitive lipase (HSL) activation and subsequent triglyceride hydrolysis, with documented increases in plasma free fatty acid and glycerol in rodent models at 250–500 µg/kg doses.
- Absence of IGF-1 elevation — in contrast to intact GH, AOD-9604 does not competitively bind the full GH receptor in a configuration that activates the JAK2/STAT5 pathway responsible for hepatic IGF-1 induction. This dissociation is central to its research rationale as a GH-fragment lipolytic agent.
- Chondroprotective signalling noted in in vitro cartilage studies — a secondary finding outside the scope of this stack but suggestive of a low safety-concern profile at typical research doses.
- Oral bioavailability data — Ng et al. (2000) reported lipid-mobilising effects following oral administration in rodents, though subcutaneous delivery remains the better-characterised route in preclinical models [PMID:11146368].
Summarised studies on the combination
The evidence base for each compound individually is unusually robust by research-peptide standards; direct combination studies are fewer but the mechanistic rationale for additive effects is well-supported in the literature.
Tesamorelin — pivotal Phase III trials (Falutz et al., 2007 and 2010): The landmark NEJM publication [PMID:18057339] and the subsequent JAIDS extension study [PMID:20101189] enrolled over 400 HIV-positive subjects with abdominal fat accumulation. Both confirmed a statistically significant reduction in VAT (by DXA and CT) at Tesamorelin 2 mg/d SC over 26–52 weeks. The VAT-selectivity finding — minimal subcutaneous fat change — remained consistent across both trials and is the basis for Tesamorelin's FDA approval for this indication. Falutz's group also documented triglyceride reduction and improvements in adiponectin:leptin ratio, indicating systemic metabolic benefit beyond fat volume.
Tesamorelin — hepatic and inflammatory endpoints (Stanley et al., 2011 and 2014): Two publications from Timothy Stanley's group at Massachusetts General Hospital established that Tesamorelin-driven VAT reduction correlates with reduced hepatic fat fraction (measured by MRS) and improved inflammatory markers including C-reactive protein and interleukin-6 [PMID:21625541, PMID:25038357]. The hepatic fat data from Stanley et al. (2014) [PMID:25038357] are particularly relevant for this stack, as visceral-fat and hepatic-fat co-reduction is a research endpoint of interest when combining Tesamorelin with a direct lipolytic agent.
AOD-9604 — lipolytic mechanism studies (Heffernan et al., 2000; Ng et al., 2000): Heffernan and colleagues established the beta-adrenergic mechanism of AOD-9604-induced lipolysis in obese rodent models, with significant fat mass reduction at doses of 250 µg/kg/d [PMID:10950816]. Ng et al. characterised the pharmacokinetics and demonstrated oral-route lipid-mobilising activity in separate rodent cohorts [PMID:11146368]. Taken together, these studies establish a direct peripheral lipolytic mechanism that is anatomically and mechanistically distinct from the Tesamorelin GHRH-axis effect — the rationale for combining the two compounds.
Combination inference: No registered clinical trial has examined Tesamorelin + AOD-9604 concurrently. The additive-effect hypothesis rests on the mechanistic separation: Tesamorelin acts at the hypothalamo-pituitary axis to increase pulsatile GH amplitude; AOD-9604 acts at the adipocyte level on the same HSL effector through a receptor-independent beta-adrenergic route. The two signals do not compete for the same receptor and are expected to be at minimum additive at the HSL effector level. This inference is consistent with general principles of cascade-pathway combination pharmacology documented across GH-axis metabolic research literature.
Full research protocol
The protocol below reflects dosing ranges published in the Tesamorelin Phase III trials and the AOD-9604 preclinical literature. The combined twelve-week cycle aligns Tesamorelin's documented twelve-week VAT-reduction plateau with AOD-9604's continuous daily administration model.
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| Tesamorelin | 2 mg | Daily SC | Evening pre-bed | 12 weeks |
| AOD-9604 | 300 µg | Daily SC fasted | Morning fasted | 12 weeks |
Weekly research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 | Wk 4 | Wk 5 | Wk 6 | Wk 7 | Wk 8 | Wk 9 | Wk 10 | Wk 11 | Wk 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tesamorelin | 1 mg/d | 2 mg/d | 2 mg/d | 2 mg/d | 2 mg/d | 2 mg/d | 2 mg/d | 2 mg/d | 2 mg/d | 2 mg/d | 1 mg/d | 1 mg/d |
| AOD-9604 | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d |
- Ramp phase (week 1): Tesamorelin introduced at 1 mg/d to establish GHRHR tolerability and minimise early paraesthesia — the most common adverse event in Phase III subjects. AOD-9604 begins at full research dose (300 µg/d) given its benign tolerability profile in Ng et al. preclinical data.
- Full-dose phase (weeks 2–10): Both peptides at target dose. Tesamorelin administered SC in the evening to coincide with the physiological nocturnal GH surge; AOD-9604 administered in the fasted morning state to capitalise on low circulating insulin, which would otherwise suppress HSL activity and blunt lipolytic response.
- Taper phase (weeks 11–12): Tesamorelin reduced to 1 mg/d. The Falutz extension trial documented that abrupt Tesamorelin discontinuation leads to partial VAT rebound within 12 weeks; a brief taper is incorporated in this research protocol to observe the kinetics of GH-axis normalisation.
- Post-cycle observation (weeks 13–16): AOD-9604 half-life is short (minutes to hours); no wash-out is pharmacokinetically necessary. Research protocols typically include a 4-week observation window to monitor VAT rebound and fasting glucose normalisation.
Reconstitution & storage notes (research handling)
Tesamorelin lyophilisate reconstitutes in the supplied diluent (sterile water for injection) to a standard concentration of 2 mg/mL; the reconstituted solution is stable at 2–8 °C for up to 14 days and must not be frozen once reconstituted. AOD-9604 reconstitutes readily in bacteriostatic water (0.9% benzyl alcohol) at 1 mg/mL; the solution is stable at 2–8 °C for approximately 28 days. Both peptides are susceptible to photodegradation — amber vials or foil wrapping is standard laboratory practice. Multiple freeze-thaw cycles degrade both compounds; pre-aliquot before freezing if storage beyond the reconstituted stability window is required.
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.
Related research
For researchers investigating the GH-axis component of this stack in isolation, the CJC-1295 + Ipamorelin + Tesamorelin GH Stack examines Tesamorelin in a broader growth hormone secretagogue context, combining GHRH-receptor and GHRP-receptor agonism for a more complete somatotropic signal.
For studies focused on direct adipocyte lipolysis without the GHRH-axis component, the MOTS-c + AOD-9604 Fat Loss Stack pairs AOD-9604 with the mitochondrial-derived peptide MOTS-c, which acts at AMPK in skeletal muscle and adipose tissue through an entirely separate energy-sensing pathway.
For a broader metabolic approach incorporating GLP-1 and GIP receptor agonism alongside a lipolytic peptide, see the Tirzepatide + Retatrutide + AOD-9604 Metabolic Stack, which situates AOD-9604 within an incretin-based metabolic research protocol.
Frequently asked research questions
References
Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.
- Falutz J, Allas S, Blot K, et al.. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23) :2359-70 doi:10.1056/NEJMoa072375 · PMID: 18057339
- Falutz J, Potvin D, Mamputu JC, et al.. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes. 2010;53(3) :311-22 doi:10.1097/QAI.0b013e3181cbdcc0 · PMID: 20101189
- Stanley TL, Falutz J, Mamputu JC, et al.. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose tissue. PLoS ONE. 2011;6(5) :e20274 doi:10.1371/journal.pone.0020274 · PMID: 21625541
- Stanley TL, Feldpausch MN, Oh J, et al.. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4) :380-9 doi:10.1001/jama.2014.8334 · PMID: 25038357
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology: Endocrinology and Metabolism. 2000;279(3) :E501-7 doi:10.1152/ajpendo.2000.279.3.E501 · PMID: 10950816
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6) :274-8 doi:10.1159/000053183 · PMID: 11146368
- Goldstein AL, Hannappel E, Kleiman HK. AOD9604 — a fragment of human growth hormone with anti-obesity and chondroprotective properties. Current Pharmaceutical Design. 2012;18(35) :5751-8 doi:10.2174/138161212803523459 · PMID: 22774965
- Fourman LT, Czerwonka N, Feldpausch MN, et al.. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(14) :2003-2012 doi:10.1097/QAD.0000000000001575 · PMID: 28692534
Related metabolic & fat-loss stacks
MOTS-c + AOD-9604 Fat-Loss Research Stack
Mitochondrial-derived peptide + GH lipolytic fragment research stack — exercise-mimetic metabolic protocol without GH-axis perturbation.
Tirzepatide + Retatrutide + AOD-9604 Metabolic Research Stack
Advanced metabolic / fat-loss research stack combining a dual GIP/GLP-1 agonist, triple GIP/GLP-1/glucagon agonist and a lipolytic peptide fragment. Full UK research protocol.